DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical-stage, pre-revenue biopharmaceutical company developing treatments for serious ischemic and vascular diseases, focused on preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS). Its lead candidate, DM199, is a recombinant (synthetic) form of the KLK1 protein. KLK1 is an established therapeutic modality in Asia for acute ischemic stroke, preeclampsia and other vascular diseases.

DM199's active development programs include:
- **ReMEDy2:** a pivotal Phase 2/3 trial in AIS, which has passed its 200-participant interim analysis threshold, with the interim analysis expected in Q1 2027.
- **Investigator-sponsored Phase 2 trial:** conducted in South Africa, covering late-onset PE (Part 1a completed; Part 1b planned), early-onset PE (Part 2 planned) and early-onset FGR (Part 3, with the first two cohorts enrolled).
- **Company-sponsored Phase 2 early-onset PE dose-finding study:** authorized by Health Canada and conditionally by the EMA, with UK expansion planned.

The company is also working toward a U.S. IND for PE. It funds operations through equity financing and held [USD:34900000] in cash, cash equivalents and short-term investments as of September 30, 2026. Updated Nov 12, 2026